{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:55:54Z","timestamp":1794081354243,"version":"4.8.0"},"reference-count":171,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T00:00:00Z","timestamp":1450828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:p>Clostridium difficile epidemiology has changed in recent years, with the emergence of highly virulent types associated with severe infections, high rates of recurrences and mortality. Antibiotic resistance plays an important role in driving these epidemiological changes and the emergence of new types. While clindamycin resistance was driving historical endemic types, new types are associated with resistance to fluoroquinolones. Furthermore, resistance to multiple antibiotics is a common feature of the newly emergent strains and, in general, of many epidemic isolates. A reduced susceptibility to antibiotics used for C. difficile infection (CDI) treatment, in particular to metronidazole, has recently been described in several studies. Furthermore, an increased number of strains show resistance to rifamycins, used for the treatment of relapsing CDI. Several mechanisms of resistance have been identified in C. difficile, including acquisition of genetic elements and alterations of the antibiotic target sites. The C. difficile genome contains a plethora of mobile genetic elements, many of them involved in antibiotic resistance. Transfer of genetic elements among C. difficile strains or between C. difficile and other bacterial species can occur through different mechanisms that facilitate their spread. Investigations of the fitness cost in C. difficile indicate that both genetic elements and mutations in the molecular targets of antibiotics can be maintained regardless of the burden imposed on fitness, suggesting that resistances may persist in the C. difficile population also in absence of antibiotic selective pressure. The rapid evolution of antibiotic resistance and its composite nature complicate strategies in the treatment and prevention of CDI. The rapid identification of new phenotypic and genotypic traits, the implementation of effective antimicrobial stewardship and infection control programs, and the development of alternative therapies are needed to prevent and contain the spread of resistance and to ensure an efficacious therapy for CDI.<\/jats:p>","DOI":"10.1177\/2049936115622891","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T21:25:12Z","timestamp":1450905912000},"page":"23-42","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":167,"title":["Recent advances in the understanding of antibiotic resistance in\n                    <i>Clostridium difficile<\/i>\n                    infection"],"prefix":"10.1177","volume":"3","author":[{"given":"Patrizia","family":"Spigaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,12,23]]},"reference":[{"key":"bibr1-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.8.2348-2353.2001"},{"key":"bibr2-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2003.00559.x"},{"key":"bibr3-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.05.015"},{"key":"bibr4-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2013.12.018"},{"key":"bibr5-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/15.3.319"},{"key":"bibr6-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1139\/w2012-002"},{"key":"bibr7-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.12299"},{"key":"bibr8-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn313"},{"key":"bibr9-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00533-15"},{"key":"bibr10-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/136.5.701"},{"key":"bibr11-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61266-4"},{"key":"bibr12-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6701(98)90019-6"},{"key":"bibr13-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1136\/gut.27.10.1169"},{"key":"bibr14-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.5.741"},{"key":"bibr16-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023014"},{"key":"bibr15-2049936115622891","doi-asserted-by":"publisher","DOI":"10.4161\/mge.19297"},{"key":"bibr17-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0607-z"},{"key":"bibr18-2049936115622891","doi-asserted-by":"publisher","DOI":"10.3201\/eid1404.071023"},{"key":"bibr20-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2009.09.009"},{"key":"bibr19-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00974-12"},{"key":"bibr21-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2010.04.008"},{"key":"bibr22-2049936115622891","first-page":"41","volume":"6","author":"Chaparro-Rojas F.","year":"2013","journal-title":"Infect Drug Resist"},{"key":"bibr23-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075471"},{"key":"bibr24-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082622"},{"key":"bibr25-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70080-3"},{"key":"bibr26-2049936115622891","unstructured":"Clinical and Laboratory Standards Institute (2012) Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Eighth Edition. CLSI document M11-A8."},{"key":"bibr27-2049936115622891","unstructured":"Clinical and Laboratory Standards Institute (2015) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25."},{"key":"bibr28-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-12-130"},{"key":"bibr29-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/596315"},{"key":"bibr30-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01980-12"},{"key":"bibr31-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/23.4.623"},{"key":"bibr32-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12418"},{"key":"bibr33-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/gbe\/evt204"},{"key":"bibr35-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.08.011"},{"key":"bibr34-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.09.004"},{"key":"bibr36-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3418-3421.2002"},{"key":"bibr38-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl398"},{"key":"bibr37-2049936115622891","doi-asserted-by":"publisher","DOI":"10.3201\/eid1303.060771"},{"key":"bibr39-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis335"},{"key":"bibr40-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2013.01.004"},{"key":"bibr41-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2014.08.002"},{"key":"bibr42-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01912.x"},{"key":"bibr43-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-147-10-2717"},{"key":"bibr45-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki357"},{"key":"bibr44-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00082-09"},{"key":"bibr46-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.09.017"},{"key":"bibr47-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06581-11"},{"key":"bibr48-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh296"},{"key":"bibr49-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/382084"},{"key":"bibr50-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00840-13"},{"key":"bibr51-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/10.suppl_A.23"},{"key":"bibr55-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/520984"},{"key":"bibr54-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01536-07"},{"key":"bibr53-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00625-11"},{"key":"bibr52-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis339"},{"key":"bibr56-2049936115622891","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.5189"},{"key":"bibr57-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/596703"},{"key":"bibr58-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1039"},{"key":"bibr60-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914322107"},{"key":"bibr59-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2478"},{"key":"bibr61-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.09.012"},{"key":"bibr62-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00548-13"},{"key":"bibr63-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7016.1345"},{"key":"bibr64-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1021\/jm5016846"},{"key":"bibr65-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00496-10"},{"key":"bibr66-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911253412203"},{"key":"bibr67-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2009.08.004"},{"key":"bibr68-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.041053-0"},{"key":"bibr69-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00224-07"},{"key":"bibr70-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6701(03)00115-4"},{"key":"bibr72-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0469"},{"key":"bibr71-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.03.015"},{"key":"bibr73-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv220"},{"key":"bibr74-2049936115622891","doi-asserted-by":"crossref","unstructured":"Krutova, M., Matejkova, J., Tkadlec, J. and Nyc, O. (2015) Antibiotic profiling of\n                      Clostridium difficile\n                      ribotype 176\u2009-\u2009A multidrug resistant relative to\n                      C. difficile\n                      ribotype 027.\n                      Anaerobe\n                      . DOI: 10.1016\/j.anaerobe.2015.07.009.","DOI":"10.1016\/j.anaerobe.2015.07.009"},{"key":"bibr75-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2290-9"},{"key":"bibr76-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2014.09.004"},{"key":"bibr77-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.072082-0"},{"key":"bibr78-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt302"},{"key":"bibr79-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis319"},{"key":"bibr80-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408913"},{"key":"bibr81-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00191-12"},{"key":"bibr82-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00964-09"},{"key":"bibr84-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"bibr83-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis338"},{"key":"bibr85-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053757"},{"key":"bibr87-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1563"},{"key":"bibr86-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1021\/jm5016846"},{"key":"bibr88-2049936115622891","doi-asserted-by":"crossref","unstructured":"Mac Aog\u00e1in, M., Kilkenny, S., Walsh, C., Lindsay, S., Moloney, G., Morris, T.\n                      et\u00a0al.\n                      (2015) Identification of a novel mutation at the primary dimer interface of GyrA conferring fluoroquinolone resistance in\n                      Clostridium difficile\n                      .\n                      JGAR\n                      , in press. DOI: 10.1016\/j.jgar.2015.09.007.","DOI":"10.1016\/j.jgar.2015.09.007"},{"key":"bibr89-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051590"},{"key":"bibr90-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/659156"},{"key":"bibr91-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05100-11"},{"key":"bibr93-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks420"},{"key":"bibr92-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02350-14"},{"key":"bibr94-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.53"},{"key":"bibr96-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-136-7-1343"},{"key":"bibr97-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.2.305"},{"key":"bibr98-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.06193-11"},{"key":"bibr95-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmic.2014.12.005"},{"key":"bibr99-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/430311"},{"key":"bibr101-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/502539"},{"key":"bibr100-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/522654"},{"key":"bibr102-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1089\/fpd.2013.1648"},{"key":"bibr103-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2014.07.007"},{"key":"bibr104-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00342-08"},{"key":"bibr105-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1845-5"},{"key":"bibr106-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2014.04.007"},{"key":"bibr107-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05588-11"},{"key":"bibr108-2049936115622891","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v5.i1.1"},{"key":"bibr109-2049936115622891","unstructured":"Optimer Pharmaceuticals, Inc. (2011) Anti-Infective Drugs Advisory Committee Briefing Document: Dificid\u2122 (fidaxomicin tablets) for the treatment of\n                      Clostridium difficile\n                      infection (CDI), also known as\n                      Clostridium\n                      difficile-associated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM249354.pdf (accessed 5 December 2015)."},{"key":"bibr110-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.041087-0"},{"key":"bibr112-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00524-08"},{"key":"bibr111-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2013.05.009"},{"key":"bibr114-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1041104"},{"key":"bibr113-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/430315"},{"key":"bibr115-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050978"},{"key":"bibr116-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1974.tb43276.x"},{"key":"bibr117-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.058875-0"},{"key":"bibr119-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46213-0"},{"key":"bibr118-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(09)70016-0"},{"key":"bibr120-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2011.06.013"},{"key":"bibr121-2049936115622891","doi-asserted-by":"publisher","DOI":"10.3201\/eid1309.061116"},{"key":"bibr122-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268811002627"},{"key":"bibr123-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2015.03.003"},{"key":"bibr124-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-147-5-1243"},{"key":"bibr125-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2011.00283.x"},{"key":"bibr126-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.3.419"},{"key":"bibr127-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03352-12"},{"key":"bibr128-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00598-08"},{"key":"bibr129-2049936115622891","unstructured":"Salix Pharmaceuticals, Ltd (2003) posting date. Salix receives FDA notification that rifaximin amendment considered a complete response. Salix Pharmaceuticals, Raleigh, NC, 10 December. Available at: http:\/\/www.businesswire.com\/news\/home\/20031210005070\/en\/Salix-Receives-FDA-Notification-Rifamixin-Amendment-Considered (accessed 5 December 2015)."},{"key":"bibr130-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.3.615"},{"key":"bibr131-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1086\/514117"},{"key":"bibr132-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2007.03.009"},{"key":"bibr133-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis337"},{"key":"bibr134-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1038\/ng1830"},{"key":"bibr135-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000149"},{"key":"bibr136-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/tru042"},{"key":"bibr137-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt477"},{"key":"bibr140-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl105"},{"key":"bibr141-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2007.723"},{"key":"bibr143-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.47738-0"},{"key":"bibr142-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00957-07"},{"key":"bibr139-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01252-08"},{"key":"bibr138-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02482-09"},{"key":"bibr144-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr292"},{"key":"bibr145-2049936115622891","doi-asserted-by":"crossref","unstructured":"Spigaglia, P., Barbanti, F., Morandi, M., Moro, M. and Mastrantonio, P. (2015) Diagnostic testing for\n                      Clostridium difficile\n                      in Italian microbiological laboratories.\n                      Anaerobe\n                      , in press. DOI: 10.1016\/j.anaerobe.2015.11.002.","DOI":"10.1016\/j.anaerobe.2015.11.002"},{"key":"bibr146-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2550-2553.2005"},{"key":"bibr147-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2014.10.003"},{"key":"bibr148-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.45682-0"},{"key":"bibr149-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2011.07.030"},{"key":"bibr150-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.042010-0"},{"key":"bibr151-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-12"},{"key":"bibr152-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2014.08.005"},{"key":"bibr153-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2013.186"},{"key":"bibr154-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.036194-0"},{"key":"bibr155-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.01.004"},{"key":"bibr156-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1089\/fpd.2014.1790"},{"key":"bibr201-2049936115622891","doi-asserted-by":"crossref","unstructured":"Vuotto, C., Moura, I., Barbanti, F., Donelli, G., Spigaglia, P. (2015) Sub-inhibitory concentrations of metronidazole increase biofilm formation in\n                      Clostridium difficile strains. Pathog Dis\n                      , in press. DOI: 10.1093\/femspd\/ftv114.","DOI":"10.1093\/femspd\/ftv114"},{"key":"bibr157-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.12.002"},{"key":"bibr158-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00210-06"},{"key":"bibr161-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.057117-0"},{"key":"bibr160-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2014.0015"},{"key":"bibr159-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04503-14"},{"key":"bibr162-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1080\/2159256X.2015.1006111"},{"key":"bibr163-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2013.02.016"},{"key":"bibr164-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1186\/1751-0147-55-23"},{"key":"bibr165-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.1.43"},{"key":"bibr166-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.8.1213"},{"key":"bibr167-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/17.12.4877"},{"key":"bibr168-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(85)90206-9"},{"key":"bibr169-2049936115622891","doi-asserted-by":"publisher","DOI":"10.3390\/molecules18066230"},{"key":"bibr170-2049936115622891","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02115-14"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2049936115622891","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2049936115622891","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2049936115622891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:56:58Z","timestamp":1777593418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2049936115622891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,23]]},"references-count":171,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1177\/2049936115622891"],"URL":"https:\/\/doi.org\/10.1177\/2049936115622891","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,23]]}}}